Navigation Links
GeoVax Labs Reports 2012 First Quarter Financial Results
Date:5/15/2012

of Health (NIH). This compares to $893,002 of grant revenue reported for the same period in 2011. As of March 31, 2012, there is approximately $3.3 million in unused IPCAVD grant funds available for use through August 31, 2012 (the end of the original project period).

Research and development (R&D) expenses were $1,072,354 for the three months ended March 31, 2012, compared with $838,467 for the comparable period in 2011. R&D expenses include direct costs funded by the IPCAVD grant, as well as vaccine manufacturing costs and expenses related to the Phase 1/2 clinical trial, being sponsored by GeoVax, of the Company's therapeutic HIV vaccine. Costs associated with the Phase 2a clinical trial of GeoVax's preventative HIV vaccine, being conducted by the HVTN, are being funded directly by the NIH and are therefore not reflected in GeoVax's financial statements. General and administrative (G&A) expenses were $512,818 and $661,813 for the three months ended March 31, 2012 and 2011, respectively.

GeoVax reported cash balances of $2,240,486 at March 31, 2012, as compared to $1,167,980 at December 31, 2011. Summarized financial information is attached. Further information concerning the Company's financial position and results of operations are included in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission.

About GeoVax's TechnologyGeoVax's unique two component vaccine, a recombinant DNA and a recombinant modified vaccinia Ankara (MVA), is designed to stimulate both anti-HIV T cell and anti-HIV antibody immune responses. GeoVax's DNA and MVA vaccines are used in a prime/boost protocol in which priming is done with the DNA and boosting with the MVA. Both the DNA and MVA express the three major proteins of the AIDS virus: Gag, Pol, and Env, and produce non-infectious virus-like-particles. GeoVax's vaccines are unique in expressing virus-like particles that display the trimeric membrane bound form of the HIV-
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. GeoVax Labs CEO Update Letter to Shareholders
2. GeoVax Labs First Patient Inoculated in Phase 1/2 Clinical Trial for HIV/AIDS Therapeutic Vaccine
3. GeoVax Phase 2a Clinical Trial Completes Enrollment
4. GeoVax $3.6 Million Award Increased to $4.4 Million by U.S. Government
5. GeoVax Labs, Inc. Announces Second Quarter Financial Results
6. GeoVax Labs HIV/AIDS Vaccine Development Leadership to be Highlighted During 2011 World Vaccine Congress
7. GeoVax Announces Publication of Phase 1 Clinical Trial in The Journal of Infectious Diseases
8. GeoVax Launches a Second Clinical Site to Test the Therapeutic Benefit of its HIV Vaccine
9. David A. Dodd Appointed Chairman of the Board of GeoVax Labs
10. GeoVax Announces Expansion of Phase 2a Human HIV/AIDS Vaccine Trial
11. GeoVax Awarded Federal Grant Under the Qualifying Therapeutic Discovery Project Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... Delaware , United States , ... or "Invion"), is pleased to announce that it has entered ... institutional investor in the United States ... A$1.001 million ("Placement") by the issue of 71,500,000 million fully-paid ... share. The Company has also agreed to ...
(Date:9/1/2015)... OAKS, Calif. and BRUSSELS ... AMGN ) and UCB (Euronext Brussels: UCB) ... (STudy evaluating effect of RomosozUmab Compared with Teriparatide ... for fracture pReviously treated with bisphosphonatE therapy). The ... statistically significant difference in favor of romosozumab in ...
(Date:9/1/2015)... LAS VEGAS , Sept. 1, 2015  Dr. ... DigiPath Labs , the cannabis testing subsidiary of ... United Patients Group about the lack of consistency ... with the online resource for medical cannabis information, she ... hurting patients because their lack of uniform requirements makes ...
Breaking Medicine Technology:Invion Announces Private Placement to US Institutional Investor 2Invion Announces Private Placement to US Institutional Investor 3Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 2Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 3Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 4Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 5Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 6Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 7Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 8Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 9DigiPath Labs CSO Dr. Cindy Orser Calls for Uniform Standards for Cannabis Safety Testing 2DigiPath Labs CSO Dr. Cindy Orser Calls for Uniform Standards for Cannabis Safety Testing 3
... Zimmer Holdings, Inc. (NYSE: ZMH ; SIX: ... conference call will be broadcast live over the Internet on ... news release detailing the quarterly results will be made available ... call. The live audio webcast can be ...
... Varian Medical Systems (NYSE: VAR ), today ... the company,s ongoing growth and safety initiatives. ... company, has been named Chief Operating Officer with responsibility ... sale of all Varian products and services throughout the ...
Cached Medicine Technology:Zimmer Holdings Announces Live Audio Webcast and Conference Call of Third Quarter 2011 Results 2Varian Medical Systems Announces New Management Positions 2Varian Medical Systems Announces New Management Positions 3Varian Medical Systems Announces New Management Positions 4
(Date:9/2/2015)... ... 2015 , ... Pentec Health, Inc., a national leader in outsourced pharmacy services, ... consecutive year. Less than 5 % of this year’s 5000 honorees share the “six-time” ... Pentec’s 3-year revenue growth rate of 65% sustained its most recent achievement. As an ...
(Date:9/2/2015)... ... September 02, 2015 , ... Dr. Robert G. ... he is now certified in “Systema”: a Russian martial art system that is also ... , Systema , which dates back to the 10th century, is a ...
(Date:9/2/2015)... ... September 02, 2015 , ... Mobile working is increasingly more important, as business ... everywhere new mobile apps are being launched, and mobile device usage as a whole ... of their work and personal lives. What's more people are expecting mobile versions of ...
(Date:9/1/2015)... Spring Lake, NJ (PRWEB) , ... September 01, ... ... physician, has a reputation for the telling the truth about medicine and health, ... has created a video blog, where he plans to regularly debunk certain misconceptions ...
(Date:9/1/2015)... Paul- Eagan (PRWEB) , ... September 01, 2015 , ... For many men, the first ... chin. Men were often forced to wear a looser fitting shirt with a collar ... their neck, sliding a finger between their collar and skin all day because it’s uncomfortable. ...
Breaking Medicine News(10 mins):Health News:Pentec Health Once Again Named One of the Fastest-Growing Private Companies in America 2Health News:Dr. Robert G. Schwartz Achieves Certification in Russian Martial Art “Systema” and Focuses on Integrating Techniques & Principles into Health Care Delivery 2Health News:Dr. Robert G. Schwartz Achieves Certification in Russian Martial Art “Systema” and Focuses on Integrating Techniques & Principles into Health Care Delivery 3Health News:New Mobility Experience From Winscribe 2Health News:New Mobility Experience From Winscribe 3Health News:Dr. Michael Rothman, NJ’s Leading Holistic Doctor, Presents a Video Blog that Discusses the Most Confusing and Interesting Current Medical Topics 2Health News:Getting Rid of Double Chins: New FDA Approved Kybella Treatment Proving Very Popular Among Professional Men at Crutchfield Dermatology 2
... excess weight worsens disease , THURSDAY, June 4 (HealthDay News) ... as many experts have thought, but it could dampen the ... , Inhaled corticosteroids are the most widely prescribed drugs to ... whom are overweight or obese. , "It raises the concern ...
... N.J., June 4 Cambrex Corporation (NYSE: CBM ... New York Stock Exchange ("NYSE") informing the Company that it ... As announced by the Company on April 14, 2009, ... standards because its average market capitalization over a consecutive 30-day ...
... night, the America,s Health Insurance Plans (AHIP) Foundation paid ... Group Health Cooperative of South Central Wisconsin, and L.A. ... designed to improve the health and environment of communities ... health plans of working with local partners in a ...
... , "Headache U" is first educational program of its kind, matches ... , CHICAGO, June 4 The National Headache Foundation (NHF) ... headache education program of its kind designed to help people with ... beginning today on the NHF website at http://www.headaches.org/headacheu/ ...
... , MIAMI, June 4 St. Jude Children,s Research Hospital(R) ... by honoring Tommy and Thalia Mottola on May ... Estefan , co-host of the popular Univision show El ... the 2009 Al-Rashid Hope Award for their commitment to children,s ...
... could lead to treatment or prevention , THURSDAY, June 4 ... a key role in cell death in Huntingdon,s disease, a ... intellectual functioning. , The discovery raises hope that drugs could ... a study in the June 5 issue of Science ...
Cached Medicine News:Health News:Obesity May Dampen Response to Asthma Meds 2Health News:AHIP Foundation Announces 2009 Community Leadership Awards 2Health News:New Online Tool Helps People With Headache Take Control, Get Relief 2Health News:New Online Tool Helps People With Headache Take Control, Get Relief 3Health News:New Online Tool Helps People With Headache Take Control, Get Relief 4Health News:Photos: Tommy & Thalia Mottola Honored at 7th Annual FedEx/St. Jude Angels & Stars Gala 2Health News:Photos: Tommy & Thalia Mottola Honored at 7th Annual FedEx/St. Jude Angels & Stars Gala 3Health News:Discovery Sheds Light on Huntington's Disease 2Health News:Discovery Sheds Light on Huntington's Disease 3
... standard, corrected curve trial lenses are ground with ... Marco refractors and are invaluable in treating low ... other manufacturers contain a disproportionately large number of ... expensive to produce, and fewer lenses in the ...
The LM-990A is the most completely automatic lensemeter ever created. It even measured monocular and binocular PD automatically....
... has made the LM-770 the easiest ... Technicians can be trained to operate ... instruction. The instrument tells the user ... A flashing indicator alerts the user ...
... designed to perform precise and accurate ... one-third the space of traditional examinations. ... refractors, automatic or digital lensmeters and ... EPIC enables the operator to call ...
Medicine Products: